ОбзорГрафикПрофильОсновная статистикаФинансовые показателиНовости
Деривативы
TraderScreen

RECORDATI ORD/  IT0003828271  /

Euronext Milan
15.11.2024  17:36:37 Изменение -0.85 Объем сделки Бид17:40:00 Предложение17:40:00 Рыночная капитализация Дивидендная доходность Коэффициент Цена/Доход
51.20EUR -1.63% 279,968
Оборот: 14.39 млн		 50.75Величина цены спроса: 9 52.05Величина цены предложения: 11 10.55 млрдEUR 2.34% 27.05
GlobeNewswire 23.03.2021 RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S AN...
GlobeNewswire 22.02.2021 RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING INCOME AND NET INCOME. EBI...
GlobeNewswire 29.01.2021 RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES
GlobeNewswire 30.11.2020 RECORDATI: MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEA...
GlobeNewswire 29.10.2020 RECORDATI: PROFIT GROWTH IN THE FIRST NINE MONTHS OF 2020. REVENUES -0.6%, EBITDA +7.1%, ADJUSTED NE...
GlobeNewswire 01.10.2020 RECORDATI: MERGER BY ABSORPTION OF FIMEI S.P.A. AND ROSSINI INVESTIMENTI S.P.A. INTO RECORDATI S.P....
GlobeNewswire 21.09.2020 RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION
GlobeNewswire 30.07.2020 RECORDATI ANNOUNCES POSITIVE FIRST HALF 2020 RESULTS. REVENUES +2.3%, EBITDA +11.4%, ADJUSTED NET IN...
GlobeNewswire 17.06.2020 RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S D...
GlobeNewswire 07.05.2020 RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES +12.1%, EBITDA +20.1%
GlobeNewswire 29.04.2020 RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018)
GlobeNewswire 08.04.2020 Recordati Rare Diseases now holds Isturisa® European MA
GlobeNewswire 26.03.2020 RECORDATI SUBMITS NEW DRUG APPLICATION FOR ISTURISA® IN JAPAN
GlobeNewswire 18.03.2020 RECORDATI CONTRIBUTES TO SUPPORT HOSPITALS AND PATIENTS IN THE FACE OF THE EPIDEMIOLOGIC EMERGENCY D...
GlobeNewswire 18.03.2020 BOARD APPROVES THE 2019 ACCOUNTS. SALES € 1,481.8 MILLION (+9.6%), EBITDA € 544.0 MILLION (+9.0%). ...
GlobeNewswire 14.02.2020 RECORDATI: PRELIMINARY 2019 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITS. SALES +9.6%. EBIT...
GlobeNewswire 15.01.2020 RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED
GlobeNewswire 15.11.2019 RECORDATI: CHMP ADOPTS POSITIVE OPINION FOR ISTURISA® (OSILODROSTAT)
GlobeNewswire 31.10.2019 RECORDATI ANNOUNCES GROWTH IN THE FIRST NINE MONTHS 2019. REVENUES +8.6%, EBITDA +7.8%, OPERATING IN...
GlobeNewswire 23.10.2019 RECORDATI: ACQUISITION OF WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699) COMPLETED
GlobeNewswire 30.07.2019 RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA(1) +7.4%, NET INCOME +6.1%
GlobeNewswire 12.07.2019 RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699)
GlobeNewswire 24.06.2019 RECORDATI RARE DISEASES, A WORLDWIDE LEADER IN RARE DISEASES AND ORPHAN DRUGS
GlobeNewswire 08.05.2019 RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2019. NEW THREE YEAR BUSINESS PLAN APPROVED
GlobeNewswire 15.04.2019 RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY